Circassia Pharmaceuticals Plc Circassia Welcomes New NICEAsthma Guidelines (8188X)
November 29 2017 - 2:01AM
UK Regulatory
TIDMCIR
RNS Number : 8188X
Circassia Pharmaceuticals Plc
29 November 2017
Circassia Welcomes New NICE Guidelines Recommending Use of FeNO
Testing in Asthma Diagnosis
Oxford, UK - 29 November 2017: Circassia Pharmaceuticals plc
("Circassia" or "the Company"; LSE: CIR), a specialty
pharmaceutical company focused on respiratory disease, welcomes the
publication of new clinical guidelines by the UK's National
Institute for Health and Care Excellence (NICE), which recommend
the use of fractional exhaled nitric oxide (FeNO) testing as part
of asthma diagnosis. Circassia's NIOX(R) products are novel
point-of-care FeNO measurement devices, which are available in many
countries across Europe, including the UK, as well as the United
States, China, Japan and a range of other territories.
The new NICE guidelines* recommend the use of FeNO testing as
part of comprehensive diagnostic algorithms for adults, children
and young people. In particular, NICE recommends FeNO testing for
adults when a diagnosis of asthma is being considered, and
consideration of a FeNO measurement in children and young people if
there is diagnostic uncertainty after initial assessment and normal
spirometry, or obstructive spirometry with negative bronchodilator
reversibility. Additionally, the health economic model included in
the guidelines concluded that FeNO testing was part of the most
cost-effective diagnostic pathway for adults.
Steve Harris, Circassia's CEO, said: "We welcome these new NICE
guidelines, which highlight the importance of FeNO testing in
asthma diagnosis and its role in providing an objective measure of
airway inflammation. With asthma diagnosis currently based
principally on a thorough history taken by an experienced
clinician, we look forward to working closely with healthcare
professionals and commissioners to make FeNO testing more widely
available."
About asthma
Asthma is a chronic inflammatory respiratory disease that often
begins in childhood, but can affect people of any age. The disease
is characterised by attacks (exacerbations) of breathlessness and
wheezing of varying severity and frequency, which if left untreated
can be life-threatening. Asthma is a common condition, with the
World Health Organisation estimating 235 million people have the
condition worldwide. Asthma affects approximately 25 million people
in the United States and over 5 million in the UK.
About NIOX(R)
Th2 or type 2 airway inflammation is the major underlying cause
of asthma. NIOX(R) is based on the discovery that patients with Th2
or type 2 driven airway inflammation generally have higher than
normal levels of nitric oxide in their exhaled breath. By measuring
the concentration of this fractional exhaled nitric oxide (FeNO),
NIOX(R) enables clinicians to evaluate airway inflammation in
patients with underlying asthma. As a result, Circassia's NIOX(R)
products are used to assist asthma management around the world.
Circassia markets NIOX(R) directly to healthcare professionals in
the United States, United Kingdom and Germany and through a network
of distributors in a range of other countries.
About Circassia
Circassia is a world-class specialty pharmaceutical business
focused on respiratory disease. In addition to its market-leading
NIOX(R) products, the Company recently established a collaboration
with AstraZeneca in the US in which it promotes the chronic
obstructive pulmonary disease (COPD) treatment Tudorza(R), and has
the US commercial rights to late-stage COPD product Duaklir(R).
Circassia's development pipeline includes a range of respiratory
medicines. The Company's lead asthma treatment targets substitution
of GSK's Flixotide(R) pMDI and was approved in the UK. Circassia is
also developing a direct substitute for Seretide(R) pMDI, and its
pipeline includes a number of inhaled medicines for COPD, including
single and combination dose products. For more information on
Circassia please visit www.circassia.com.
Contacts
Circassia
Steve Harris, Chief Executive Tel: +44 (0) 1865 405
Officer 560
Julien Cotta, Chief Financial
Officer
Rob Budge, Corporate Communications
JP Morgan Cazenove
James Mitford / James Tel: +44 (0) 20 7742 4000
Deal
Numis Securities
Clare Terlouw / Freddie Tel: +44 (0) 20 7260 1000
Barnfield
FTI Consulting
Ben Atwell / Simon Conway Tel: +44 (0) 20 3727 1000
/ Mo Noonan
Forward-looking statements
This press release contains certain projections and other
forward-looking statements with respect to the financial condition,
results of operations, businesses and prospects of Circassia. The
use of terms such as "may", "will", "should", "expect",
"anticipate", "project", "estimate", "intend", "continue", "target"
or "believe" and similar expressions (or the negatives thereof) are
generally intended to identify forward-looking statements. These
statements are based on current expectations and involve risk and
uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements. Any of the assumptions underlying these
forward-looking statements could prove inaccurate or incorrect and
therefore any results contemplated in the forward-looking
statements may not actually be achieved. Nothing contained in this
press release should be construed as a profit forecast or profit
estimate. Investors or other recipients are cautioned not to place
undue reliance on any forward-looking statements contained herein.
Circassia undertakes no obligation to update or revise (publicly or
otherwise) any forward-looking statement, whether as a result of
new information, future events or other circumstances.
*Asthma: diagnosis and monitoring of asthma in adults, children
and young people. National Guideline Centre. Commissioned by the
National Institute for Health and Care Excellence. November
2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLIFSRLLLAFID
(END) Dow Jones Newswires
November 29, 2017 02:01 ET (07:01 GMT)
Circassia (LSE:CIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Circassia (LSE:CIR)
Historical Stock Chart
From Apr 2023 to Apr 2024